Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy
Background: The ultimate goal of hepatitis B treatment is hepatitis B surface antigen (HBsAg) seroclearance. Several factors have been suggested to be associated with the rate of HBsAg reduction in antiviral-naive or lamivudine therapy cohorts. However, there are few studies evaluating the factors d...
Main Authors: | Xia-Xia Zhang, Min-Ran Li, Hong-Li Xi, Ying Cao, Ren-Wen Zhang, Yu Zhang, Xiao-Yuan Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2016-01-01
|
Series: | Chinese Medical Journal |
Subjects: | |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2016;volume=129;issue=8;spage=929;epage=935;aulast=Zhang |
Similar Items
-
Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B
by: Mohammed Y Hasosah, et al.
Published: (2012-01-01) -
Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients
by: Chia-Chi Wang, et al.
Published: (2014-11-01) -
Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients
by: Yuan-wang Qiu, et al.
Published: (2016-02-01) -
Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
by: Nobuharu Tamaki, et al.
Published: (2020-06-01) -
Dynamic changes in B7-H1 expression on peripheral blood mononuclear cells in chronic hepatitis B patients treated with entecavir
by: WU Liexiu
Published: (2014-09-01)